Kyowa Hakko Kirin Announces Top-Line Results of Global Phase 3
... primary endpoint in patients with Parkinson’s disease. This study was to evaluate the efficacy of KW-6002 (20 mg or 40 mg once-daily treatment for 12 weeks) in patients with moderate to severe Parkinson’s disease with "wearing-off phenomenon" on levodopa therapy, in comparison with placebo, and to a ...
... primary endpoint in patients with Parkinson’s disease. This study was to evaluate the efficacy of KW-6002 (20 mg or 40 mg once-daily treatment for 12 weeks) in patients with moderate to severe Parkinson’s disease with "wearing-off phenomenon" on levodopa therapy, in comparison with placebo, and to a ...
Projet INCO-DEV / CE 2001
... considered sufficient for supporting the non-clinical safety of the proposed 4-drug combination 2. since extensive human experience exists as regard to the drugs being tested, the non-clinical investigations would not be a progress-limiting factor 3. the timing of the clinical trials would not depen ...
... considered sufficient for supporting the non-clinical safety of the proposed 4-drug combination 2. since extensive human experience exists as regard to the drugs being tested, the non-clinical investigations would not be a progress-limiting factor 3. the timing of the clinical trials would not depen ...
Appendix S5.
... these parasites provides a certain reassurance for the possibility of finding human therapeutic uses for this substance. ...
... these parasites provides a certain reassurance for the possibility of finding human therapeutic uses for this substance. ...
Opsona Therapeutics Ltd. announces preliminary
... As of December 2016, 24 eligible patients have been enrolled, 11 at 5 mg dose and 13 at 10 mg/kg. A total of 15 (75%) patients are evaluable for response. Hematological improvement has been seen in 53% (8/15) with 3 (20%) patients achieving transfusion independence and of these 2/5 (40%) were receiv ...
... As of December 2016, 24 eligible patients have been enrolled, 11 at 5 mg dose and 13 at 10 mg/kg. A total of 15 (75%) patients are evaluable for response. Hematological improvement has been seen in 53% (8/15) with 3 (20%) patients achieving transfusion independence and of these 2/5 (40%) were receiv ...
Fampridine-SR - Centre for Medicines Optimisation
... disturbances, mood and vertigo. The NICE clinical guideline on multiple sclerosis, May 2012 ...
... disturbances, mood and vertigo. The NICE clinical guideline on multiple sclerosis, May 2012 ...
gemfibrozil
... apolipoproteins AI and AII. Epidemiological studies have shown that both low HDLcholesterol and high LDL-cholesterol are independent risk factors for coronary heart disease. In the Helsinki Heart Study, a large randomized double-blind, placebo-controlled, primary prevention trial in 4081 male patien ...
... apolipoproteins AI and AII. Epidemiological studies have shown that both low HDLcholesterol and high LDL-cholesterol are independent risk factors for coronary heart disease. In the Helsinki Heart Study, a large randomized double-blind, placebo-controlled, primary prevention trial in 4081 male patien ...
Rizatriptan Orifarm tablet ENG SmPC
... The efficacy of rizatriptan oral lyophilisates in paediatric patients (12 to 17 years of age) was evaluated in a multicenter, randomized, double-blind, placebo-controlled, parallel group study (n=570). The patient population was required to be historically non-responsive to NSAIDs and acetaminophen ...
... The efficacy of rizatriptan oral lyophilisates in paediatric patients (12 to 17 years of age) was evaluated in a multicenter, randomized, double-blind, placebo-controlled, parallel group study (n=570). The patient population was required to be historically non-responsive to NSAIDs and acetaminophen ...
Scleroderma Association of Manitoba
... not a problem with low doses (7.5-15 mg/wk) Concern with higher doses like 150 mg 2. NSAIDs + gingko (herb) Case reports-potential for increased bleeding; use with caution or avoid ...
... not a problem with low doses (7.5-15 mg/wk) Concern with higher doses like 150 mg 2. NSAIDs + gingko (herb) Case reports-potential for increased bleeding; use with caution or avoid ...
ethacrynic acid (eth-a-krin-ikas-id) - DavisPlus
... Use Cautiously in: Severe liver disease (may precipitate hepatic coma; concurrent use with potassium-sparing diuretics may be necessary); Electrolyte depletion; ⫽ Canadian drug name. ...
... Use Cautiously in: Severe liver disease (may precipitate hepatic coma; concurrent use with potassium-sparing diuretics may be necessary); Electrolyte depletion; ⫽ Canadian drug name. ...
RIFAMPICIN in combination with Isoniazid RIFAMPICIN
... It is rapidly absorbed and diffuses readily into all fluids and tissues. The plasma half-life, which is genetically determined, varies from less than one hour in fast acetylators to more than three hours in slow acetylators. It is largely excreted in the urine within 24 hours, mostly as inactive met ...
... It is rapidly absorbed and diffuses readily into all fluids and tissues. The plasma half-life, which is genetically determined, varies from less than one hour in fast acetylators to more than three hours in slow acetylators. It is largely excreted in the urine within 24 hours, mostly as inactive met ...
Merck`s Zepatier shows high response rates in hep C trials
... The C-EDGE CO-STAR assessed the drug in patients with chronic HCV GT1, GT4 and/or GT6 infection taking an opioid agonist therapy such as methadone or buprenorphine. Data show that 94 percent and 96 percent of patients achieved SVR24 in the blinded and open-label arms of the trial, respectively. The ...
... The C-EDGE CO-STAR assessed the drug in patients with chronic HCV GT1, GT4 and/or GT6 infection taking an opioid agonist therapy such as methadone or buprenorphine. Data show that 94 percent and 96 percent of patients achieved SVR24 in the blinded and open-label arms of the trial, respectively. The ...
MGB-BP-3 - MGB Biopharma
... is generic; in addition it does not encourage appearance of vancomycin-resistant enterococci (VRE). Vancomycin is only used in severe cases or non-responders • Utility of these antibiotics is limited due to recurrence; either re-infection with same pathogen or new infection ...
... is generic; in addition it does not encourage appearance of vancomycin-resistant enterococci (VRE). Vancomycin is only used in severe cases or non-responders • Utility of these antibiotics is limited due to recurrence; either re-infection with same pathogen or new infection ...
methimazole (meth-im-a-zole) - DavisPlus
... qrisk of agranulocytosis with phenothiazines. May alter response to warfarin and digoxin. ...
... qrisk of agranulocytosis with phenothiazines. May alter response to warfarin and digoxin. ...
OFLOMED® 200 mg Tablets Dear patient, Please read
... inflammation, or rupture of a tendon, if any symptom of an allergic reaction occurs or if severe diarrhea occurs during treatment. -This drug should be used with caution in patients with a known or suspected central nervous system disorder that may predispose to seizures or in the presence of other ...
... inflammation, or rupture of a tendon, if any symptom of an allergic reaction occurs or if severe diarrhea occurs during treatment. -This drug should be used with caution in patients with a known or suspected central nervous system disorder that may predispose to seizures or in the presence of other ...
Efficacy of nicergoline in dementia and other age
... were homogeneous in nature despite including patients observed for periods of time ranging from 2 months to 12 months. There was a difference in favour of the active treatment in reducing the behavioural symptoms described by this scale, -5.18 points [-8.03, -2.33]. This scale has a maximum of 133 p ...
... were homogeneous in nature despite including patients observed for periods of time ranging from 2 months to 12 months. There was a difference in favour of the active treatment in reducing the behavioural symptoms described by this scale, -5.18 points [-8.03, -2.33]. This scale has a maximum of 133 p ...
ORIGINAL AND GENERIC AEDs IN THE TREATMENT OF EPILEPSY
... Objective. This article presents the state-of-the-art concerning the possible consequences of substitution of original drugs with generic drugs (and vice versa) and substitution of one generic drug with another generic drug in the treatment of epilepsy (exchange of pharmaceutical preparations). Revi ...
... Objective. This article presents the state-of-the-art concerning the possible consequences of substitution of original drugs with generic drugs (and vice versa) and substitution of one generic drug with another generic drug in the treatment of epilepsy (exchange of pharmaceutical preparations). Revi ...
Xamic - Renata Limited
... plasminogen activation of both exogenous activators like streptokinase and endogenous ones like urokinase and the plasminogen tissue activator. This fact is particularly important for the clinical use of Xamic ®, because it ensures an antihemorrhagic activity with an antifibrinolytic mechanism under ...
... plasminogen activation of both exogenous activators like streptokinase and endogenous ones like urokinase and the plasminogen tissue activator. This fact is particularly important for the clinical use of Xamic ®, because it ensures an antihemorrhagic activity with an antifibrinolytic mechanism under ...
atropine (at-ro-peen) - DavisPlus
... disease of the GI tract. Use Cautiously in: Intra-abdominal infections; Prostatic hyperplasia; Chronic renal, hepatic, pulmonary, or cardiac disease; OB, Lactation: Safety not established; IV administration may produce fetal tachycardia; Pedi: Infants with Down syndrome have increased sensitivity to ...
... disease of the GI tract. Use Cautiously in: Intra-abdominal infections; Prostatic hyperplasia; Chronic renal, hepatic, pulmonary, or cardiac disease; OB, Lactation: Safety not established; IV administration may produce fetal tachycardia; Pedi: Infants with Down syndrome have increased sensitivity to ...
Reviewer 1 - WHO archives
... The dose of epinephrine should be 0.01 mg/kg, up to a maximum of 0.30 mg. This presents a dilemma for clinicians in that the prefilled autoinjector kits use doses of only 0.15 and 0.30 mg/ kg, making the precise dosing of children and adolescents difficult if not impossible. While there is little ...
... The dose of epinephrine should be 0.01 mg/kg, up to a maximum of 0.30 mg. This presents a dilemma for clinicians in that the prefilled autoinjector kits use doses of only 0.15 and 0.30 mg/ kg, making the precise dosing of children and adolescents difficult if not impossible. While there is little ...
Product Information
... “In vitro” experiments with human liver microsomes have demonstrated that lercanidipine shows some degree of inhibition of CYP 3A4 and CYP 2D6, at concentrations 160- and 40-fold, respectively, higher than those reached at peak in the plasma after the dose of 20mg. Moreover, interaction studies in h ...
... “In vitro” experiments with human liver microsomes have demonstrated that lercanidipine shows some degree of inhibition of CYP 3A4 and CYP 2D6, at concentrations 160- and 40-fold, respectively, higher than those reached at peak in the plasma after the dose of 20mg. Moreover, interaction studies in h ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.